艾尔巴韦格拉瑞韦片治疗尿毒症血液透析患者丙型肝炎病毒感染的临床疗效及对不良反应的影响

Clinical Efficacy of Elbavir Glarevir Tablets in the Treatment of Hepatitis C Virus Infection in Uremic Hemodialysis Patients and Its Influence on Adverse Reactions

目的分析艾尔巴韦格拉瑞韦片(EBR/GZR)治疗尿毒症行血液透析治疗继发丙型肝炎病毒(HCV)感染的效果及安全性。方法选取2019年1~12月收治的69例尿毒症血液透析继发HCV感染的患者作为研究对象,给予艾尔巴韦格拉瑞韦治疗,观察治疗前后肝肾功能、观察临床疗效及不良反应。结果治疗后,患者ALB、ALT、GGT、AST水显著低于治疗前(P<0.05),肾功能指标较治疗前无明显变化(P>0.05);本组69例患者中,早期应答率为75.36%(52/69),完全应答率50.72%(35/69),部分应答率36.23%(25/69),无应答5.80%(4/69);治疗过程中,患者发生的主要不良反应主要涉及消化系统、肌肉、神经系统及皮肤,包括恶心、呕吐、上腹部不适、乏力、肌肉酸痛、头晕、皮肤瘙痒,均为轻中度症状,经对症处理后均好转,无一例因不良反应中断治疗。结论艾尔巴韦格拉瑞韦治疗尿毒症继发HCV感染的临床效果理想,可有效改善患者肝功能,早期应答率高,不良反应轻微,安全性好。

Objective To analyze the efficacy and safety of elbavir glarevir tablets(EBR/GZR)in the treatment of uremia by hemodialysis in the treatment of secondary hepatitis C virus(HCV)infection.Methods Sixty-nine patients with uremic hemodialysis secondary to HCV infection who were admitted from January 2019 to December 2019 were selected as the research subjects,and treated with elbavir glarevir.Observe the liver and kidney function before and after treatment,and observe the clinic Efficacy and adverse reactions.Results After treatment,the patient’s ALB,ALT,GGT,and AST levels were significantly lower than before treatment(P<0.05),and renal function indexes did not change significantly from before treatment(P>0.05).Among 69 patients in this group,the early response rate It was 75.36%(52/69),the complete response rate was 50.72%(35/69),the partial response rate was 36.23%(25/69),and the non-response rate was 5.80%(4/69).During the treatment,the main adverse events occurred in the patient.The reaction mainly involves the digestive system,muscles,nervous system and skin,including nausea,vomiting,upper abdominal discomfort,fatigue,muscle aches,dizziness,and skin pruritus,all of which are mild to moderate symptoms,and all improved after symptomatic treatment.No case was interrupted due to adverse reactions.Conclusion The clinical effect of elbavir glarevir in the treatment of uremia secondary to HCV infection is ideal.It can effectively improve the liver function of patients with high early response rate,mild adverse reactions and good safety.